Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PALAVY: Avelumab or Hydroxychloroquine With or Without Palbociclib to Eliminate Dormant Breast Cancer
NCT04841148Phase 2Active, not recruiting
- Sponsor
- Abramson Cancer Center
- Start
- Jun 2021
- Primary completion
- Jul 2027
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of avelumab, hydroxychloroquine, palbociclib in breast cancer, sponsored by Abramson Cancer Center. Started Jun 2021; status: active, not recruiting.
02
Drugs
avelumabhydroxychloroquinepalbociclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT04841148.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04841148.